A Phase 3 interventional study of Daprodustat and Darbepoetin alfa in Anaemia, sponsored by GlaxoSmithKline. Completed at 111 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-10-20.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 9 in phase 3, and was the 18th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 3, and was the 24th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive oral daprodustat once daily.
Drug: Daprodustat · Drug: Iron therapy
Subjects will receive darbepoetin alfa subcutaneously or intravenously.
Drug: Darbepoetin alfa · Drug: Iron therapy
Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)
Blood samples were collected from participants for Hgb measurement. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputations. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. An analysis of covariance (ANCOVA) model including randomization stratification factors Baseline Hgb and treatment was performed to obtain a point estimate and two-sided 95 percent (%) confidence interval (CI) for the treatment difference (daprodustat-darbepoetin alfa).
Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Average Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52
Total IV iron dose per participant was calculated from Day 1 to the earliest of (Week 52 visit date, first blood \[red blood cells or whole blood\] transfusion date and treatment stop date plus \[+\] 1 day) which corresponds to the time while the participant was on randomized treatment and before receiving a blood transfusion. Average monthly IV iron dose was calculated by Total IV iron dose divided by (/) (the number of days from Day 1 to the earliest of \[Week 52 visit date, first blood transfusion date and treatment stop date +1\] /30.4375 days). Data for participants until they underwent a red blood cells or whole blood transfusion was included in the analysis.
Time frame: Baseline (Day 1) to Week 52
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Blood Pressure (MAP) at Week 52
SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using mixed model repeated measures (MMRM) model.
Time frame: Baseline (Day 1) and Week 52
Change From Baseline in SBP, DBP, MAP at End of Treatment
SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. End of treatment value for the blood pressure parameters were defined as the latest value on or before the last non-zero dose date plus (+) 1 day. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using ANCOVA model.
Time frame: Baseline (Day 1) and end of treatment (last on-treatment value until Week 52)
Blood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years
BP exacerbation event is defined (based on post-dialysis BP) as SBP \>=25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; or DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.
Time frame: Up to Week 52
Number of Participants With at Least One Blood Pressure Exacerbation Event During Study
BP exacerbation was defined (based on post-dialysis BP) as: SBP \>=25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one blood pressure exacerbation event is presented.
Time frame: Up to Week 52
Change From Baseline in Post-randomization Hgb at Week 52
Blood samples were collected from participants for Hgb measurements. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1) and Week 52
Number of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)
Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as number of participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.
Time frame: Weeks 28 to 52
Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.
Time frame: Weeks 28 to 52
Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.
Time frame: Weeks 28 to 52
Number of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria
Number of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.
Time frame: Up to Week 52
Change From Baseline in Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain, general health, mental health, role-emotional (role limitations caused by emotional problems), role-physical (role limitations caused by physical problems), social functioning, physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52
Change From Baseline in Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1), Weeks 28 and 52
Change From Baseline in Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1), Weeks 28 and 52
Change From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52
EQ-5D-5L consists of 2 concepts-EQ-5D-5L descriptive system and EQ Visual Analogue Scale (EQ-VAS). EQ-5D-5L is self-assessment questionnaire, consisting of 5items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state(e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health), higher the score better the health status. Change from Baseline was calculated as post-dose visit value-Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.
Time frame: Baseline (Day 1) and Week 52
Change From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 52
The EQ-5D-5L consists of 2 concepts -EQ-5D-5L descriptive system and EQ-VAS. The EQ-5D-5L is a self-assessment questionnaire, consisting of five items covering five dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by a five-point Likert scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). The range for the EQ-5D-5L index score is 0 to 1 with '0' is worst health and '1' is full health. The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst health one can imagine and 100 represents the best health one can imagine. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1) and Week 52
Change From Baseline in Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Week 52
CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy/Weak scale consisting of 10 items; 2.Chest Pain/Shortness of Breath scale consisting of 4 items; and 3.Cognitive scale consisting of 3 items. The 4 CKD-AQ single items are: (shortness of breath, no activity), (severity-short breath, resting), (difficulty standing for long time) and (difficulty sleeping). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1) and Week 52
Change From Baseline in Patient Global Impression of Severity (PGI-S)
The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52
Plasma Concentration of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)
Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic (PK) analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12. Pharmacokinetic Population comprised of participants for whom a pharmacokinetic sample was obtained and analyzed.
Time frame: Pre-dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12
Observed Concentration at Dosing Interval (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)
Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.
Time frame: Pre-Dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12
Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)
Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.
Time frame: Pre-Dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12
This was a multicenter study conducted across 14 countries. Participants were randomized to receive either Daprodustat or Darbepoetin alfa.
| Milestone | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Started | 157 | 155 |
| Completed | 155 | 151 |
| Not completed | 2 | 4 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
Blood samples were collected from participants for Hgb measurement. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputations. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. An analysis of covariance (ANCOVA) model including randomization stratification factors Baseline Hgb and treatment was performed to obtain a point estimate and two-sided 95 percent (%) confidence interval (CI) for the treatment difference (daprodustat-darbepoetin alfa).
| Grams per deciliter | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52) | 1.02 ± 0.086 | 1.12 ± 0.085 |
Total IV iron dose per participant was calculated from Day 1 to the earliest of (Week 52 visit date, first blood \[red blood cells or whole blood\] transfusion date and treatment stop date plus \[+\] 1 day) which corresponds to the time while the participant was on randomized treatment and before receiving a blood transfusion. Average monthly IV iron dose was calculated by Total IV iron dose divided by (/) (the number of days from Day 1 to the earliest of \[Week 52 visit date, first blood transfusion date and treatment stop date +1\] /30.4375 days). Data for participants until they underwent a red blood cells or whole blood transfusion was included in the analysis.
| Milligram | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Average Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52 | 144.7 ± 10.90 | 125.3 ± 10.97 |
SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using mixed model repeated measures (MMRM) model.
| Millimeter of mercury | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| SBP | -3.57 ± 2.063 | -6.80 ± 2.931 |
| DBP | 0.21 ± 1.216 | -4.01 ± 1.650 |
| MAP | -0.95 ± 1.364 | -5.05 ± 1.894 |
SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. End of treatment value for the blood pressure parameters were defined as the latest value on or before the last non-zero dose date plus (+) 1 day. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using ANCOVA model.
| Millimeter of mercury | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| SBP | -3.23 ± 1.659 | -3.14 ± 1.664 |
| DBP | 0.60 ± 1.016 | -1.39 ± 1.020 |
| MAP | -0.68 ± 1.092 | -1.97 ± 1.096 |
BP exacerbation event is defined (based on post-dialysis BP) as SBP \>=25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; or DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.
| Events per 100 participant year | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Blood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years | 352.50 (268.89 to 462.09) | 350.00 (267.72 to 457.56) |
BP exacerbation was defined (based on post-dialysis BP) as: SBP \>=25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one blood pressure exacerbation event is presented.
| Participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Number of Participants With at Least One Blood Pressure Exacerbation Event During Study | 91 | 100 |
Blood samples were collected from participants for Hgb measurements. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Grams per deciliter | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in Post-randomization Hgb at Week 52 | 1.17 ± 0.117 | 1.13 ± 0.115 |
Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as number of participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.
| Participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Number of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52) | 86 | 87 |
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.
| Percentage of days | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis | 57.0 (0.0 to 100.0) | 54.7 (0.0 to 100.0) |
Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.
| Percentage of days | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis | 57.0 (0.0 to 100.0) | 54.7 (0.0 to 100.0) |
Number of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.
| Participants | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Number of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria | 5 | 5 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=88,86 | 0.79 ± 0.648 | 1.18 ± 0.658 |
| Week 12, n=88,88 | 1.67 ± 0.627 | 0.54 ± 0.631 |
| Week 28, n=80,74 | 0.94 ± 0.697 | 0.45 ± 0.725 |
| Week 52, n=67,65 | 0.61 ± 0.755 | 1.93 ± 0.774 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=88,86 | 0.10 ± 0.822 | 0.76 ± 0.839 |
| Week 12, n=88,88 | 0.08 ± 0.813 | 1.60 ± 0.824 |
| Week 28, n=80,74 | -0.02 ± 0.905 | 0.30 ± 0.942 |
| Week 52, n=67,65 | -0.95 ± 1.029 | -0.72 ± 1.051 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain, general health, mental health, role-emotional (role limitations caused by emotional problems), role-physical (role limitations caused by physical problems), social functioning, physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Bodily pain: Week 8, n=88,86 | -0.41 ± 0.833 | -0.55 ± 0.843 |
| Bodily pain: Week 12, n=88,88 | -0.13 ± 0.892 | -0.06 ± 0.895 |
| Bodily pain: Week 28, n=80,74 | 1.08 ± 0.941 | -1.26 ± 0.976 |
| Bodily pain: Week 52, n=67,65 | -2.00 ± 1.084 | 0.61 ± 1.109 |
| General health: Week 8, n=88,86 | 0.80 ± 0.662 | 0.75 ± 0.674 |
| General health: Week 12, n=88,88 | 0.87 ± 0.651 | 0.59 ± 0.658 |
| General health: Week 28, n=80,74 | 0.63 ± 0.693 | 0.37 ± 0.720 |
| General health: Week 52, n=67,65 | 0.40 ± 0.823 | 0.58 ± 0.841 |
| Mental health: Week 8, n=88,86 | -0.90 ± 0.825 | 0.25 ± 0.841 |
| Mental health: Week 12, n=88,88 | 0.01 ± 0.707 | 1.42 ± 0.712 |
| Mental health: Week 28, n=80,74 | -0.69 ± 0.866 | -0.21 ± 0.902 |
| Mental health: Week 52, n=67,65 | -0.53 ± 0.994 | -0.27 ± 1.013 |
| Role-emotional: Week 8, n=88,86 | 0.83 ± 0.880 | 0.50 ± 0.896 |
| Role-emotional: Week 12, n=88,88 | 0.55 ± 0.934 | -0.07 ± 0.946 |
| Role-emotional: Week 28, n=80,74 | 0.91 ± 0.929 | 0.39 ± 0.964 |
| Role-emotional: Week 52, n=67,65 | -1.60 ± 1.193 | -0.11 ± 1.216 |
| Role-physical: Week 8, n=88,86 | 1.34 ± 0.806 | 2.64 ± 0.818 |
| Role-physical: Week 12, n=88,88 | 2.39 ± 0.712 | 1.69 ± 0.716 |
| Role-physical: Week 28, n=80,74 | 0.62 ± 0.799 | 1.49 ± 0.829 |
| Role-physical: Week 52, n=67,65 | 1.49 ± 0.895 | 2.22 ± 0.913 |
| Social functioning: Week 8, n=88,86 | 0.52 ± 0.929 | 1.55 ± 0.947 |
| Social functioning: Week 12, n=88,88 | 0.98 ± 0.774 | 2.15 ± 0.783 |
| Social functioning: Week 28, n=80,74 | 1.03 ± 0.943 | 0.95 ± 0.980 |
| Social functioning: Week 52, n=67,65 | 0.39 ± 1.085 | -0.33 ± 1.105 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 28, n=80,74 | -0.08 ± 0.866 | 0.95 ± 0.902 |
| Week 52, n=67,65 | 0.16 ± 0.907 | 1.61 ± 0.925 |
The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 28, n=80,74 | 0.55 ± 0.863 | 0.83 ± 0.898 |
| Week 52, n=67,65 | 0.14 ± 0.947 | 1.58 ± 0.973 |
EQ-5D-5L consists of 2 concepts-EQ-5D-5L descriptive system and EQ Visual Analogue Scale (EQ-VAS). EQ-5D-5L is self-assessment questionnaire, consisting of 5items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state(e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health), higher the score better the health status. Change from Baseline was calculated as post-dose visit value-Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52 | 0.00 ± 0.041 | -0.03 ± 0.040 |
The EQ-5D-5L consists of 2 concepts -EQ-5D-5L descriptive system and EQ-VAS. The EQ-5D-5L is a self-assessment questionnaire, consisting of five items covering five dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by a five-point Likert scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). The range for the EQ-5D-5L index score is 0 to 1 with '0' is worst health and '1' is full health. The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst health one can imagine and 100 represents the best health one can imagine. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Change From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 52 | 3.4 ± 3.27 | 6.8 ± 3.28 |
CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy/Weak scale consisting of 10 items; 2.Chest Pain/Shortness of Breath scale consisting of 4 items; and 3.Cognitive scale consisting of 3 items. The 4 CKD-AQ single items are: (shortness of breath, no activity), (severity-short breath, resting), (difficulty standing for long time) and (difficulty sleeping). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Tired/Low energy/Weak domain | -2.36 ± 2.007 | 4.07 ± 1.990 |
| Chest pain/Shortness of breath domain | -1.83 ± 1.593 | 2.28 ± 1.557 |
| Cognitive domain | -4.17 ± 1.893 | 2.43 ± 1.852 |
| Shortness of breath, no activity | -1.90 ± 1.861 | 1.14 ± 1.826 |
| Severity-short breath, Resting | -4.16 ± 1.869 | 0.12 ± 1.836 |
| Difficulty standing for long time | -2.00 ± 2.812 | 3.30 ± 2.754 |
| Difficulty sleeping | -5.27 ± 2.667 | 1.26 ± 2.611 |
The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.
| Scores on a scale | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| Week 8, n=100,100 | 0.16 ± 0.091 | -0.11 ± 0.092 |
| Week 12, n=100,103 | 0.02 ± 0.077 | -0.03 ± 0.077 |
| Week 28, n=92,85 | 0.09 ± 0.086 | -0.07 ± 0.089 |
| Week 52, n=75,77 | 0.22 ± 0.106 | 0.04 ± 0.105 |
Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic (PK) analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12. Pharmacokinetic Population comprised of participants for whom a pharmacokinetic sample was obtained and analyzed.
| Nanogram per milliliter | Daprodustat 1 mg | Daprodustat 2 mg | Daprodustat 4 mg | Daprodustat 6 mg | Daprodustat 8 mg | Daprodustat 10 mg | Daprodustat 12 mg | Daprodustat 16 mg | Daprodustat 24 mg |
|---|---|---|---|---|---|---|---|---|---|
| Daprodustat: Pre-Dose, n=19,26,20,18,1,1,0,0,0 | 2.118 ± 5.0030 | 1.015 ± 3.1451 | 0.5787 ± 1.5718 | 2.867 ± 6.6142 | 0.1030 ± NA | 0.1090 ± NA | — | — | — |
| Daprodustat: 0.5 hour, n=19,26,20,18,0,1,0,0,0 | 5.675 ± 8.4998 | 4.664 ± 8.7508 | 10.27 ± 20.425 | 12.58 ± 23.742 | — | 145.0 ± NA | — | — | — |
| Daprodustat: 1 hour, n=19,26,20,18,1,1,0,0,0 | 12.34 ± 13.435 | 21.45 ± 42.160 | 36.78 ± 62.497 | 45.48 ± 48.765 | 0.9120 ± NA | 79.60 ± NA | — | — | — |
| Daprodustat: 2 hours, n=19,26,20,18,1,1,0,0,0 | 12.74 ± 9.9019 | 20.36 ± 22.210 | 54.68 ± 80.284 | 55.62 ± 51.471 | 32.00 ± NA | 27.60 ± NA | — | — | — |
| Daprodustat: 3 hours, n=19,26,19,18,1,1,0,0,0 | 7.719 ± 5.9144 | 15.58 ± 13.694 | 43.34 ± 66.295 | 56.49 ± 74.357 | 25.30 ± NA | 11.00 ± NA | — | — | — |
| GSK2391220: Pre-Dose, n=19,26,20,18,1,1,0,0,0 | 0.7106 ± 0.64028 | 2.124 ± 2.8721 | 2.087 ± 2.1371 | 3.560 ± 4.2255 | 4.450 ± NA | 6.560 ± NA | — | — | — |
| GSK2391220: 0.5 hour, n=19,25,20,18,1,1,0,0,0 | 0.7602 ± 0.67950 | 1.807 ± 2.2007 | 1.822 ± 2.1355 | 2.410 ± 2.8243 | 3.950 ± NA | 6.740 ± NA | — | — | — |
| GSK2391220: 1 hour, n=18,26,20,18,1,1,0,0,0 | 1.123 ± 0.76920 | 1.752 ± 1.8589 | 1.965 ± 2.2830 | 3.140 ± 2.4856 | 3.900 ± NA | 10.00 ± NA | — | — | — |
| GSK2391220: 2 hours, n=19,26,20,18,1,1,0,0,0 | 1.745 ± 1.3160 | 2.969 ± 2.4659 | 4.008 ± 4.4522 | 6.336 ± 4.3723 | 4.700 ± NA | 16.20 ± NA | — | — | — |
| GSK2391220: 3 hours, n=19,26,19,18,1,1,0,0,0 | 1.911 ± 1.2274 | 3.535 ± 2.7203 | 5.553 ± 6.5157 | 9.372 ± 6.6452 | 6.090 ± NA | 16.60 ± NA | — | — | — |
| GSK2506104: Pre-Dose, n=19,26,20,18,1,1,0,0,0 | 1.270 ± 0.96071 | 3.508 ± 4.2066 | 3.879 ± 3.4207 | 5.921 ± 5.8981 | 8.710 ± NA | 9.500 ± NA | — | — | — |
| GSK2506104: 0.5 hour, n=19,26,20,18,1,1,0,0,0 | 1.197 ± 0.85104 | 2.788 ± 2.9893 | 3.315 ± 3.4249 | 4.015 ± 3.7385 | 7.740 ± NA | 8.110 ± NA | — | — | — |
| GSK2506104: 1 hour, n=19,26,20,18,1,1,0,0,0 | 1.364 ± 0.96292 | 2.610 ± 2.4761 | 3.268 ± 3.4808 | 4.333 ± 3.0505 | 7.460 ± NA | 12.40 ± NA | — | — | — |
| GSK2506104: 2 hours, n=19,26,20,18,1,1,0,0,0 | 1.966 ± 1.3440 | 3.583 ± 2.8427 | 4.989 ± 5.2109 | 7.130 ± 4.5105 | 8.930 ± NA | 19.60 ± NA | — | — | — |
| GSK2506104: 3 hours, n=19,26,19,18,1,1,0,0,0 | 2.190 ± 1.3898 | 4.145 ± 3.1757 | 6.503 ± 7.5130 | 9.942 ± 7.0616 | 10.10 ± NA | 22.00 ± NA | — | — | — |
| GSK2531401: Pre-Dose, n=19,26,20,18,1,1,0,0,0 | 1.642 ± 1.4836 | 2.729 ± 1.8934 | 3.750 ± 3.8006 | 5.111 ± 4.0632 | 5.660 ± NA | 7.760 ± NA | — | — | — |
| GSK2531401: 0.5 hour, n=19,26,20,18,1,1,0,0,0 | 1.427 ± 1.2870 | 2.170 ± 1.6621 | 3.263 ± 3.8737 | 3.800 ± 2.8722 | 4.960 ± NA | 6.460 ± NA | — | — | — |
| GSK2531401: 1 hour, n=19,26,20,18,1,1,0,0,0 | 1.399 ± 1.4595 | 1.979 ± 1.6316 | 3.146 ± 4.0334 | 3.776 ± 3.4411 | 4.810 ± NA | 6.630 ± NA | — | — | — |
| GSK2531401: 2 hours, n=19,26,20,18,1,1,0,0,0 | 1.690 ± 1.6309 | 2.338 ± 2.1467 | 3.711 ± 5.0223 | 4.892 ± 4.7877 | 5.190 ± NA | 8.290 ± NA | — | — | — |
| GSK2531401: 3 hours, n=19,26,19,18,1,1,0,0,0 | 1.847 ± 1.7376 | 2.734 ± 2.6846 | 4.715 ± 7.2788 | 6.631 ± 7.1049 | 5.760 ± NA | 10.20 ± NA | — | — | — |
Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.
| Nanogram per milliliter | Daprodustat 1 mg | Daprodustat 2 mg | Daprodustat 4 mg | Daprodustat 6 mg | Daprodustat 8 mg | Daprodustat 10 mg | Daprodustat 12 mg | Daprodustat 16 mg | Daprodustat 24 mg |
|---|---|---|---|---|---|---|---|---|---|
| Daprodustat | 2.118 ± 5.0030 | 1.015 ± 3.1451 | 0.5787 ± 1.5718 | 2.867 ± 6.6142 | 0.1030 ± NA | 0.1090 ± NA | — | — | — |
| GSK2391220 | 0.7106 ± 0.64028 | 2.124 ± 2.8721 | 2.087 ± 2.1371 | 3.560 ± 4.2255 | 4.450 ± NA | 6.560 ± NA | — | — | — |
| GSK2506104 | 1.270 ± 0.96071 | 3.508 ± 4.2066 | 3.879 ± 3.4207 | 5.921 ± 5.8981 | 8.710 ± NA | 9.500 ± NA | — | — | — |
| GSK2531401 | 1.642 ± 1.4836 | 2.729 ± 1.8934 | 3.750 ± 3.8006 | 5.111 ± 4.0632 | 5.660 ± NA | 7.760 ± NA | — | — | — |
Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.
| Nanogram per milliliter | Daprodustat 1 mg | Daprodustat 2 mg | Daprodustat 4 mg | Daprodustat 6 mg | Daprodustat 8 mg | Daprodustat 10 mg | Daprodustat 12 mg | Daprodustat 16 mg | Daprodustat 24 mg |
|---|---|---|---|---|---|---|---|---|---|
| Daprodustat | 21.74 ± 10.998 | 32.29 ± 40.166 | 76.92 ± 81.867 | 100.2 ± 74.086 | 32.00 ± NA | 145.0 ± NA | — | — | — |
| GSK2391220 | 2.160 ± 1.2596 | 4.139 ± 3.3561 | 5.780 ± 6.2840 | 10.36 ± 6.3377 | 6.090 ± NA | 16.60 ± NA | — | — | — |
| GSK2506104 | 2.477 ± 1.3625 | 5.212 ± 4.5562 | 7.075 ± 7.1313 | 11.60 ± 6.8731 | 10.10 ± NA | 22.00 ± NA | — | — | — |
| GSK2531401 | 2.283 ± 1.8210 | 3.565 ± 2.6091 | 5.328 ± 6.9034 | 7.836 ± 6.6199 | 5.760 ± NA | 10.20 ± NA | — | — | — |
Collected over All-cause mortality, treatment emergent non-serious adverse events and serious adverse events were collected up to follow-up visit (Week 58). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daprodustat | 17/157 (10.8%) | 52/157 (33.1%) | 76/157 (48.4%) |
| Darbepoetin Alfa | 12/155 (7.7%) | 51/155 (32.9%) | 74/155 (47.7%) |
| Event | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| PneumoniaInfections and infestations | 4/157 | 7/155 |
| Fluid overloadMetabolism and nutrition disorders | 5/157 | 3/155 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 1/157 | 4/155 |
| Device malfunctionProduct Issues | 4/157 | 0/155 |
| PeritonitisInfections and infestations | 1/157 | 3/155 |
| SepsisInfections and infestations | 0/157 | 3/155 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/157 | 3/155 |
| Acute myocardial infarctionCardiac disorders | 0/157 | 3/155 |
| Abdominal painGastrointestinal disorders | 0/157 | 3/155 |
| Post procedural infectionInfections and infestations | 3/157 | 0/155 |
| Event | Daprodustat | Darbepoetin Alfa |
|---|---|---|
| HypertensionVascular disorders | 27/157 | 24/155 |
| Dialysis hypotensionVascular disorders | 21/157 | 15/155 |
| DiarrhoeaGastrointestinal disorders | 14/157 | 10/155 |
| HeadacheNervous system disorders | 12/157 | 9/155 |
| Upper respiratory tract infectionInfections and infestations | 7/157 | 11/155 |
| VomitingGastrointestinal disorders | 11/157 | 5/155 |
| HypotensionVascular disorders | 7/157 | 9/155 |
| NasopharyngitisInfections and infestations | 7/157 | 9/155 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 7/157 | 9/155 |
| Fluid overloadMetabolism and nutrition disorders | 9/157 | 6/155 |
| Age, Continuous(Years) | Daprodustat | Darbepoetin Alfa | Total |
|---|---|---|---|
| Mean | 53.7 ± 14.31 | 55.8 ± 15.70 | 54.7 ± 15.03 |
| Sex: Female, Male(Participants) | Daprodustat | Darbepoetin Alfa | Total |
|---|---|---|---|
| Female | 61 | 57 | 118 |
| Male | 96 | 98 | 194 |
| Race/Ethnicity, Customized(Participants) | Daprodustat | Darbepoetin Alfa | Total |
|---|---|---|---|
| American Indian (AI) or Alaskan Native (AN) | 5 | 2 | 7 |
| Asian: Central/South Asian Heritage | 7 | 6 | 13 |
| Asian: East Asian Heritage | 8 | 16 | 24 |
| Asian: South East Asian Heritage | 11 | 9 | 20 |
| Black or African American | 16 | 13 | 29 |
| White: Arabic/North African Heritage | 1 | 0 | 1 |
| White: White/Caucasian/European Heritage | 109 | 107 | 216 |
| Mixed race: AI or AN and White | 0 | 2 | 2 |
Showing the first 100 of 111 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from May 2017 to primary completion in Sep 2020, 40 months.
Results were first posted in Oct 2021, 1 year after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 40 months is above that.
Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863